Changes in Surgery for Advanced Ovarian Cancer
Author Information
Author(s): Bercow Alexandra MD, Stewart Taylor MD, Bregar Amy J. MD, Gockley Allison MD, Mazina Varvara MD, Rauh-Hain J. Alejandro MD MPH, Melamed Alexander MD MPH
Primary Institution: Massachusetts General Hospital
Hypothesis
How has the surgical approach for advanced-stage ovarian cancer changed from 2010 to 2021?
Conclusion
There has been a significant shift from primary cytoreductive surgery to neoadjuvant chemotherapy followed by interval cytoreductive surgery for advanced ovarian cancer in the US.
Supporting Evidence
- From 2010 to 2021, the percentage of patients who underwent PCS fell from 70.1% to 37.2%.
- The percentage of patients who underwent ICS increased from 16.6% to 40.8% over the same period.
- There was a rise in the proportion of patients who received no surgery from 13.3% to 22.0%.
- Among patients with stage III disease, the proportion of patients who underwent PCS fell from 79.3% to 51.1%.
- NACT followed by ICS has become the most prevalent approach for the up-front treatment of advanced EOC since 2021.
Takeaway
Doctors are now using a different method to treat advanced ovarian cancer, which is better for patients than the old method.
Methodology
This retrospective cohort study analyzed patients diagnosed with stage III to IV EOC from 2010 to 2021 using the National Cancer Database.
Potential Biases
Potential biases may arise from the observational nature of the study and reliance on existing database records.
Limitations
The study is based on retrospective data, which may have inherent biases.
Participant Demographics
Mean age of participants was 63.7 years, with 63.7% having stage III disease.
Statistical Information
Confidence Interval
95% CI, 0.52-0.55
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website